Introduction and Overview

Efficacy and Safety Trends with Continuous Longterm Use of Crisaborole Ointment 2% in Patients with Mild-to-Moderate Atopic Dermatitis

Safety, Efficacy and Pharmacokinetics of Crisaborole Ointment 2% in Infants Age Three to Less Than 24 Months with Mild-to-Moderate Atopic Dermatitis

Association Between an Itch-Free State in Atopic Dermatitis Treated with Ruxolitinib Cream and Systemic Inflammatory Mediators

Dupilumab Treatment for up to Three Years Demonstrates Sustained Efficacy in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from Liberty AD Adult Open Label Extension

Patient-reported Outcome, or PROs, with Abrocitinib Treatment in Patients with Moderate to Severe Atopic Dermatitis

Peak Pruritus Numeric Rating Scale, the PPNRS, Response with Abrocitinib in Patients with Moderate to Severe Atopic Dermatitis: Results from a Randomized Phase 3 Clinical Trial

Dupilumab Treatment Results in Rapid Improvement in Itch in Adults and Adolescent Patients with Moderate to Severe Atopic Dermatitis

Treatment Patterns Among Patients with Atopic Dermatitis Using Advanced Therapies in the United States: An Analysis of a Retrospective Claims Database

Other posters of interest